Drug Neurology

Skyclarys

Payments companies reported to CMS as associated with Skyclarys. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$920Kassociated payments (2023-2025)
3,737clinicians with associated payments
1company reporting

By year

2023 $37K
2024 $286K
2025 $597K

Payments reported as associated with Skyclarys, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Neurology (Psychiatry & Neurology) $582K
Neurology With Special Qualifications In Child Neurology $120K
Pediatrics $48K
Physical Medicine & Rehabilitation $42K
Neuromuscular Medicine (Psychiatry & Neurology) $30K
Family $20K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Skyclarys

These are the largest totals companies reported as associated with Skyclarys. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Sheng-Han Kuo New York, NY Neurology (Psychiatry & Neurology) $190,457.27
Michael Soileau Georgetown, TX Neurology (Psychiatry & Neurology) $111,061.71
Khashayar Dashtipour Loma Linda, CA Neurology (Psychiatry & Neurology) $79,848.58
Nassim Rad Seattle, WA Physical Medicine & Rehabilitation $40,365.20
Susan Perlman Los Angeles, CA Neurology (Psychiatry & Neurology) $38,215.07
Melanie Taylor Grand Rapids, MI Neurology (Psychiatry & Neurology) $37,488.49
Aristotel Pena-Miches Monroe, LA Neurology With Special Qualifications In Child Neurology $35,302.27
Jonathan Strober San Francisco, CA Pediatrics $34,561.40
Christopher Gomez Chicago, IL Neurology (Psychiatry & Neurology) $34,311.25
Marisa Mcghee Winston Salem, NC Neuromuscular Medicine (Psychiatry & Neurology) $24,016.88

Prescribed Skyclarys?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.